Rentschler Appoints Mark Caswell as Vice President, US Facility Site Head
Rentschler Biopharma has appointed Mark Caswell as Vice President and Site Head. He joined Rentschler in July 2022 and is managing all operations at the company’s US facilities in Milford, MA.
Caswell has more than 25 years of experience in the biopharmaceutical industry. Prior to joining Rentschler, he worked for over six years at Lonza Biologicals, most recently as Head of Operations at the Portsmouth, NH site. Before that, he worked for many years at Sanofi Genzyme (previously Genzyme) in positions of increasing responsibility.
“I am excited to welcome Mark Caswell to the Rentschler team. His many years of experience in the biopharma and CDMO space and diverse background in various areas of operations make him the perfect leader to run our US operations,” said Frank Mathias, CEO of Rentschler. “An important part of his responsibilities will be overseeing the completion of our state-of-the-art RBMC facility, the largest expansion in Rentschler Biopharma’s 150-year history.”
The responsibilities of Martin Kessler in his role as CEO of Rentschler Biopharma Inc. have been transferred to Caswell.


most read

Oxea Returns to its Roots
Oxea is returning to its old name and its roots.

VCI Welcomes US-EU Customs Deal
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Novo Nordisk's CEO Lars Fruergaard Jørgensen Steps Down
Novo Nordisk recently announced changes to its executive leadership and Board of Directors.

Orion Announced Plans to Shut Down Carbon Black Plants
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.

Valerie Diele-Braun Leaves IMCD
Valerie Diele-Braun resigned from her position as CEO and member of the Executive Board of IMCD at the end of April for personal reasons.







